Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Up 117.6% in March

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 3,700 shares, an increase of 117.6% from the February 28th total of 1,700 shares. Based on an average daily trading volume, of 10,700 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.1% of the shares of the stock are short sold.

Scinai Immunotherapeutics Price Performance

Scinai Immunotherapeutics stock traded down $0.50 during midday trading on Friday, reaching $2.90. 144,912 shares of the company were exchanged, compared to its average volume of 276,915. Scinai Immunotherapeutics has a 1 year low of $2.23 and a 1 year high of $8.92. The company has a market capitalization of $2.47 million, a price-to-earnings ratio of -0.01 and a beta of 2.36. The firm’s 50-day simple moving average is $3.43 and its 200-day simple moving average is $3.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.16 and a current ratio of 1.16.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.